Mozobil for Autologous Hematopoietic Stem Cell Transplantation

Who May Qualify: - Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study: - Age ≥18 years - Undergoing autologous stem cell transplant for one of the following diagnoses: - Multiple myeloma - Hodgkin's lymphoma - Non-Hodgkin lymphoma - Karnofsky performance status of ≥ 60% - Patients must meet the TJUH BMT SOP guidelines for "Patient Criteria for Autologous HSCT" as specified below - your organs (liver, kidneys, etc.) are working well enough based on blood tests: - LVEF of ≥40% - Adjusted DLCO ≥45% of predicted corrected for hemoglobin - Adequate liver function as defined by a serum bilirubin \<1.8, AST or ALT \< 2.5X upper limit of normal - Serum creatinine ≤ 2.0 mg/dl and/or creatinine clearance of \> 40 ml/min (excludes multiple myeloma patients receiving high dose Melphalan conditioning) - Willingness to use contraception if childbearing potential - Has the ability to give willing to sign a consent form, or for cognitively or decisionally impaired individuals (vulnerable population), the availability of a family member or guardian to give consent and assist in the consent process - Life expectancy of \> 12 months (exclusive of the disease for which the Auto HSCT is being performed) - Patients must have undergone stem cell mobilization with the combination of G- CSF or biosimilars with plerixafor or G-CSF or biosimilars alone Who Should NOT Join This Trial: - An individual who meets any of the following criteria will be excluded from participation in this study: - Uncontrolled HIV - Uncontrolled bacterial infection - Active CNS disease - Pregnancy or lactation - Evidence of another malignancy, exclusive of a skin cancer that requires only local treatment Always talk to your doctor about whether this trial is right for you.